ResearcherHenry Ford HealthActive in the last 2 years

Jagadananda Ghosh

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2024: 1 paper

Papers 1

MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon. Last author DOI 10.3389/fonc.2024.1387535 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jitender Monga · 1 shared paper, 2024 · strength 0.26
- Paper MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-eps… DOI 10.3389/fonc.2024.1387535 ↗
Gazala Naaz Khan · 1 shared paper, 2024 · strength 0.26
- Paper MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-eps… DOI 10.3389/fonc.2024.1387535 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.